Remzi Ekici

Dr. Remzi Ekici

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Nutrition
Verified
Journal Article
Closed access
RERemzi Ekici
Remzi Ekici
AEAbdulsamet Erden
Abdulsamet Erden
SGSerdar Can Güven
Serdar Can Güven
BABerkan Armağan
Berkan Armağan
BÖBahar Özdemir
Bahar Özdemir
ŞEŞükran Erten
Şükran Erten

6 October 2026 in Saudi Journal of Gastroenterology
Verified
Journal Article
Closed access
RERemzi Ekici
Remzi Ekici
Was not provided for this article.

18 August 2026
Verified
Book
Closed access
PDF file
RERemzi Ekici
Remzi Ekici
EYEkin Kadıoğlu Yıldırım
Ekin Kadıoğlu Yıldırım
GBGalip Büyükturan
Galip Büyükturan
TBTolga Bakır
Tolga Bakır
EAEmine Gül Aydın
Emine Gül Aydın
ITİbRahim Emir Tekin
İbRahim Emir Tekin

18 August 2026
Verified
Book Chapter
Closed access
RERemzi Ekici
Remzi Ekici
Karın ağrısı, birinci basamak sağlık hizmetleri, acil tıp, iç hastalıkları ve gastroenteroloji pratiğinde en sık karşılaşılan yakınmalardan biridir. Nedenleri, iyi huylu ve kendiliğinden iyileşen durumlardan, acil müdahale gerektiren yaşamı tehdit eden rahatsızlıklara kadar değişmektedir. Klinik değerlendirme ağrının başlangıç zamanı, süresi, lokalizasyonu, şiddeti, yemek ve dışkılama ile ilişkisi, eşlik eden ateş, kusma, sarılık, kanama, kilo kaybı gibi semptomları, gebelik olasılığı, ilaç kullanımı ve önceki cerrahi öyküsü birlikte yapılmalıdır. Tanısal yaklaşım anamneze, fizik muayene, laboratuvar testleri ve radyolojik görüntülemeye göre bireyselleştirilmelidir. Bu bölümün amacı, karın ağrısı ile başvuran hastalarda alarm bulgularının doğru tanınmasını sağlamak; bu bulguların varlığına göre uygun tanısal değerlendirme ve tedavi yaklaşımlarını özetlemek; kanıta dayalı bir hasta eğitimi ve pratik bir iletişim protokolü sunmaktır. Abdominal pain is one of the most common complaints in primary care, emergency medicine, internal medicine, and gastroenterology practice. Its causes range from benign and spontaneously resolving conditions to life-threatening disorders requiring urgent intervention. Clinical evaluation should consider the time of onset, duration, localization, severity of pain, its relationship to eating and defecation, accompanying symptoms such as fever, vomiting, jaundice, bleeding, and weight loss, the possibility of pregnancy, medication use, and previous surgical history. The diagnostic approach should be individualized based on anamnesis, physical examination, laboratory tests, and radiological imaging. This section aims to ensure the correct identification of alarm signs in patients presenting with abdominal pain; to summarize appropriate diagnostic evaluation and treatment approaches based on the presence of these signs; and to provide evidence-based patient education and a practical communication protocol.

18 August 2026
Verified
Book Chapter
Closed access
RERemzi Ekici
Remzi Ekici

30 July 2026 in Medical Science and Discovery
Verified
Journal Article
Open access
PDF file
GBGalip Buyukturan
Galip Buyukturan
RERemzi Ekici
Remzi Ekici
IEIsmail Erturk
Ismail Erturk
BYBirol YILDIZ
Birol YILDIZ
RARamazan Acar
Ramazan Acar
KSKenan Saglam
Kenan Saglam
Objective: Heart failure (HF) is a common and potentially fatal clinical condition. Catestatin, a peptide derived from chromogranin A (CgA), inhibits catecholamine secretion. This study aimed to evaluate differences in plasma catestatin levels between individuals without HF and patients with HF, and to investigate the relationship between catestatin and established HF markers. GB, RE, IE, BY, RA, TO, FNA, KS Methods: A total of 60 HF patients with left ventricular ejection fraction (LVEF) ≤45% and 53 control subjects matched for factors that could influence catestatin levels were included. The absence of heart failure in control participants was confirmed by clinical assessment, review of medical records and transthoracic echocardiography. Plasma samples were collected simultaneously in aprotinin-containing tubes to prevent peptide degradation. Plasma catestatin levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: Catestatin levels were significantly higher in patients with HF (45.46 ± 16.69 ng/mL) compared with individuals without HF (37.15 ± 16.36 ng/mL) (t = 2.69, p = 0.008). Catestatin levels increased significantly with advancing NYHA functional class (Jonckheere–Terpstra test: J-T = 2.19; p = 0.029). Catestatin was positively correlated with NT-proBNP (r = 0.241; p = 0.010) and negatively correlated with LVEF (r = −0.19; p = 0.043). Catestatin was lower in patients with left ventricular hypertrophy than in those without, both within the patient group (41.39 ± 16.69 versus 49.64 ± 15.09 ng/mL; p = 0.04) and across the whole study population (37.41 ± 16.22 versus 44.04 ± 15.48 ng/mL; p = 0.03). The area under the ROC curve for catestatin in HF diagnosis was 0.635. Conclusion: Catestatin levels are associated with the presence and severity of heart failure. Its correlation with established parameters of severity and its progressive increase across NYHA functional classes indicate that catestatin may have value as a complementary neurohumoral marker in heart failure. Because the design was cross-sectional, no inference can be drawn regarding prognostic utility, and prospective evaluation is required.